生物学的安全性試験サービス市場規模、成長と動向分析レポート 2026-2033年

世界の生物学的安全性試験サービス市場の規模は、2025年に42億米ドルと評価され、2026年の47億米ドルから2033年には110億米ドルへと、2026年から2033年にかけて年平均成長率（CAGR）12.8%に達するとGrand View Researchでは予測しています。北米が市場を主導し、2025年には33.3%という最大のシェアを占めました。生物学的安全性試験サービス業界の成長は、バイオ医薬品やバイオシミラーの採用拡大、細胞・遺伝子治療への関心の高まり、そして製品の安全性に関する厳しい規制要件によって促進されています。

市場の主な動向とインサイト

• サービス別：2025年にはバイオバーデン（微生物汚染）試験サービスが19.3%の最大シェアを占めました。
• 用途別：2025年にはワクチン・治療薬分野が最大のシェアを占めました。
• 最終用途別：2025年にはバイオ医薬品企業が最大のシェアを占めました。

地域別のハイライト

• 最大の地域市場：北米（2025年時点で収益シェア33.3%）
• 最も急成長している地域市場：アジア太平洋地域（2026～2033年の期間で最高のCAGRを記録）
• 国別：2025年には米国が最大のシェアを占めました。

さらに、バイオ医薬品のパイプラインの拡大と受託試験サービスの拡充が、市場の成長をさらに加速させています。自動化、次世代シーケンシング（NGS）、ポリメラーゼ連鎖反応（PCR）法を用いた検査などの技術的進歩により、効率と精度が向上し、安全性試験の信頼性が高まっています。加えて、バイオ医薬品業界はここ数年で著しい成長を遂げています。Creative Biogene社の公表データによると、現在、約3,700種類の細胞・遺伝子治療製品がパイプラインにあり、世界中で100以上の治療法が承認されています。細胞・遺伝子治療製品のパイプライン拡大と規制当局による承認数の増加は、市場の成長を大きく牽引しています。こうした先進的な治療法では、微生物やウイルスによる汚染がないことを保証するために、厳格な安全性評価が求められます。したがって、細胞・遺伝子治療製品のパイプラインの増加に伴い、今後、これらのサービスに対する需要はさらに高まると予想されます。

また、社内での試験実施には多額の費用と専門知識が必要となるため、多くの製薬・バイオテクノロジー企業が、生物学的安全性試験を専門のサービスプロバイダーに委託するケースが増えています。医薬品開発受託機関（CRO）や医薬品開発製造受託機関（CDMO）は、費用対効果が高く、規制に適合した試験ソリューションを提供する上で重要な役割を担っています。この傾向は、創薬に注力しつつ業務の効率化を図ろうとする新興バイオ医薬品企業において特に顕著です。

用途別動向

2025年、生物学的安全性試験サービス市場において、ワクチン・治療薬セグメントが41.6%という最大の収益シェアを占め、市場を牽引しました。このセグメントの成長は、ワクチン製造やバイオ医薬品による治療において、厳格な安全性評価への需要が高いことに起因しています。特に新興感染症や季節性流行への対応に伴うワクチン開発の急速な拡大により、広範なバイオバーデン（微生物負荷）試験や無菌試験、さらにはエンドトキシン評価の必要性が高まっています。さらに、モノクローナル抗体や組換えタンパク質製剤の採用拡大も、同セグメントの成長を後押ししています。

細胞・遺伝子治療セグメントは、先進的治療法のパイプライン拡大と規制当局による審査の厳格化を背景に、予測期間中に最も高い年平均成長率（CAGR）で成長すると見込まれています。これらの治療法には、遺伝子改変細胞、ウイルスベクター、複雑な生物学的製剤などが含まれるため、ウイルス除去試験、マイコプラズマ検出、細胞株の真偽確認（認証）といった専門的な安全性試験が必要となります。世界中で約3,700品目の細胞・遺伝子治療製品が開発中であり、すでに100品目以上が承認されていることから、今後数年間で包括的な安全性試験への需要が増加すると予測されます。こうした要因が、予測期間中の市場成長を促進すると見込まれています。

本レポートは、世界、地域、および国レベルでの収益成長を予測するとともに、2021年から2033年にかけての各サブセグメントにおける最新の業界動向を分析しています。本調査において、Grand View Researchは世界の生物学的安全性試験サービス市場を、サービス、用途、最終用途、および地域に基づいて区分しています。

Biological Safety Testing Services Market Summary

The global biological safety testing services market size was valued at USD 4.2 billion in 2025 and is projected to grow from USD 4.7 billion in 2026 to USD 11.0 billion by 2033, at a CAGR of 12.8% from 2026 to 2033. North America dominated the market, accounting for the largest share of 33.3% in 2025. The growth of the biological safety testing services industry is driven by the increasing adoption of biologics and biosimilars, rising focus on cell and gene therapies, and stringent regulatory requirements for product safety.

Moreover, the growing pipeline of biopharmaceutical drugs, coupled with the expansion of contract testing services, has further fueled the market. Technological advancements such as automation, next-generation sequencing (NGS), and polymerase chain reaction (PCR)-based testing are improving efficiency and accuracy, making safety testing more reliable. Furthermore, the biopharmaceutical industry has witnessed significant growth in the past few years. According to the data published by Creative Biogene, approximately 3,700 cell and gene therapy products are in the pipeline currently, with more than 100 approved therapies globally. The growing pipeline of cell and gene therapy products, along with an increasing number of regulatory approvals, is significantly driving the market growth. These advanced therapies require stringent safety assessments to ensure the absence of microbial and viral contaminants. Thus, the growing number of cell and gene therapy product pipelines would boost the demand for these services in the coming year.

In addition, several pharmaceutical and biotechnology companies are increasingly outsourcing their biological safety testing needs to specialized service providers due to the high costs and expertise required for in-house testing. Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) play a pivotal role in providing cost-effective, regulatory-compliant testing solutions. This trend is particularly strong in emerging biopharmaceutical companies seeking to streamline operations while focusing on drug development.

Market Dynamics

Driver: Expansion of Biologics, Biosimilars, and Advanced Therapy Pipelines

One of the major drivers for the biological safety testing services market is the rapid expansion of biologics, biosimilars, vaccines, and advanced therapies, which require rigorous safety evaluation throughout development and manufacturing. Unlike conventional small molecules, biologics are produced using living systems, making them more vulnerable to microbial contamination, viral impurities, host-cell proteins, residual DNA, endotoxins, and adventitious agents. This increases the need for specialized testing across cell line development, process validation, batch release, and regulatory submission stages. The growing number of monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapy candidates is also raising the complexity and frequency of biosafety testing. Sponsors increasingly outsource these services to access validated methods, advanced analytical platforms, GMP-compliant laboratories, and regulatory documentation support without investing heavily in in-house infrastructure. As biopharma pipelines become more specialized and globalized, demand for reliable safety testing partners is expected to strengthen across both clinical and commercial manufacturing programs.

Restraint: High Testing Complexity, Cost, and Capacity Constraints

A key restraint in the biological safety testing services market is the high cost and technical complexity associated with validated biosafety testing. Tests such as viral clearance, adventitious agent detection, sterility testing, and residual host contamination analysis require specialized facilities, trained scientific personnel, validated methods, controlled environments, and extensive quality documentation. These requirements increase project cost and may create barriers for small biotechnology firms with limited development budgets. In addition, capacity constraints at established laboratories can lead to longer turnaround times, especially during periods of high biologics or vaccine manufacturing activity. Method development and validation can also become challenging for novel modalities, including cell and gene therapies, where sample availability, assay sensitivity, matrix interference, and regulatory expectations may vary significantly. These factors can delay development timelines, increase outsourcing costs, and create operational bottlenecks for sponsors managing multiple products or accelerated approval pathways.

Opportunity Analysis- Integrated Testing Solutions for Cell and Gene Therapies

One of the significant opportunities lies in developing integrated biological safety testing solutions tailored to cell and gene therapies, regenerative medicines, and other advanced biologics. These therapies involve complex manufacturing workflows, limited batch sizes, living-cell materials, viral vectors, and highly sensitive release timelines, creating strong demand for specialized sterility, mycoplasma, viral safety, endotoxin, residual DNA, and adventitious agent testing. Service providers that offer rapid testing methods, platform-based validation, sample-sparing assays, digital documentation, and regulatory-ready reporting can gain a strong competitive position. There is also a growing opportunity to support sponsors from early process development through clinical and commercial manufacturing, reducing testing fragmentation and improving submission readiness. As more advanced therapy developers move toward late-stage trials and commercialization, demand for high-quality, flexible, and modality-specific testing services is expected to drive the market. Providers with expertise in viral vectors, autologous therapies, allogeneic platforms, and accelerated batch-release testing are likely to benefit from this market.

Market Concentration & Characteristics

The market growth stage is medium, and the pace of the growth is accelerating. The biological safety testing services market is characterized by an increasing number of M&A activities, the impact of regulations, service expansion, and regional expansions.

The biological safety testing services industry is witnessing continuous innovation driven by advancements in analytical technologies and automation. The adoption of next-generation sequencing (NGS), real-time polymerase chain reaction (PCR), and high-throughput screening methods has enhanced the precision and efficiency of microbial detection and viral safety assessments.

Stringent regulatory requirements imposed by agencies such as the FDA, EMA, and ICH are major market drivers, shaping the demand for these services. Regulations mandate rigorous testing for sterility, endotoxins, mycoplasma, and viral contaminants to ensure product safety and compliance. The evolving regulatory landscape, with increasing oversight on cell and gene therapies and biosimilars, has heightened the need for advanced safety testing solutions.

Mergers and acquisitions (M&A) play a pivotal role in shaping the market, with major players acquiring specialized service providers to expand their capabilities and global reach. Leading companies such as Charles River Laboratories, Merck KGaA, and WuXi AppTec have engaged in strategic acquisitions to enhance their testing portfolios and strengthen their positions in the contract testing space.

The growing complexity of biologics, biosimilars, and advanced therapies has led to the expansion of these services. Companies are diversifying their offerings to include viral clearance studies, next-generation sterility testing, and genetic stability testing to meet the evolving demands of the industry. Contract testing organizations (CROs and CDMOs) are increasingly expanding their service portfolios to provide end-to-end solutions, catering to small and large biopharmaceutical companies.

The market is experiencing significant regional expansion, with North America, Europe, and Asia-Pacific emerging as key growth hubs. While North America leads due to a strong biopharmaceutical industry and stringent regulatory framework, Asia-Pacific is witnessing rapid growth driven by increasing biotech investments, expanding contract testing services, and favorable government initiatives.

Impact of U.S. Tariffs on the Biological Safety Testing Services market

The U.S. tariffs are expected to have an indirect but meaningful impact on the market by increasing cost pressure across laboratory operations, biopharmaceutical supply chains, and outsourced testing workflows. Biological safety testing providers rely on imported reagents, assay kits, consumables, analytical instruments, single-use components, and specialized laboratory materials. Higher duties on these inputs can increase testing costs, particularly for sterility, endotoxin, viral clearance, adventitious agent detection, and residual contamination testing. This may lead service providers to revise pricing models, renegotiate supplier contracts, or absorb part of the cost to remain competitive.

Tariffs may also encourage biopharmaceutical companies to localize testing activities within the U.S. to reduce cross-border sample movement, customs delays, and supply uncertainty. This can benefit domestic testing laboratories with established GMP infrastructure and regulatory expertise. However, smaller service providers may face margin pressure due to limited purchasing power and a weaker ability to diversify their supplier base. Global providers may respond by regionalizing supply chains, qualifying alternate vendors, expanding U.S.-based testing capacity, and strengthening inventory planning. Overall, tariffs are likely to accelerate operational resilience strategies, supplier diversification, and nearshoring of critical biosafety testing services.

Technological Advancements

Technological advancements are reshaping the biological safety testing services industry by enhancing speed, accuracy, and regulatory compliance in an increasingly complex biopharmaceutical landscape. In the market, automation and high-throughput platforms further streamline the workflow by reducing manual errors and facilitating the large-scale production of biologics and cell therapies. Besides, next-generation sequencing is increasingly focusing on contaminant detection through comprehensive, unbiased genomic analysis, while rapid microbial detection technologies, such as qPCR and ATP bioluminescence, significantly shorten testing timelines. Moreover, growing advances in cell-based assays offer ethical and reproducible alternatives to animal testing, thereby enhancing the evaluation of potency, toxicity, and immunogenicity.

Furthermore, AI, machine learning, and digitalization are expected to enhance data integrity, predictive analytics, and operational efficiency in biosafety labs, thereby driving market growth. Thus, growing innovations are anticipated to improve risk assessment, boost product release, and facilitate compliance with evolving global standards. As biologics, vaccines, and gene therapies expand rapidly, these technologies are increasingly essential to ensure product quality, patient safety, and streamlined regulatory approval, positioning the biosafety testing sector for technological growth. Thus, these factors are expected to drive the market over the forecast period.

Pricing Model Analysis

In the biological safety testing services market, pricing models play a pivotal role in aligning with clients, emphasizing catering to the varying client needs, regulatory demands, and the need for swift development timelines. It highlights milestone-based pricing, which aligns costs with project progress, making it suitable for multi-stage biologics and cell therapy programs. In this model, the payments are linked to the completion of specific tests, such as viral clearance and sterility. Value-based pricing is mentioned as a method that reflects the significance of high-sensitivity assays and rapid outputs, focusing on the impact of outcomes rather than the volume of tests. Fixed-fee models further support the maintenance of predictable costs for routine assays, enabling manufacturers to manage their budgets better and ensure compliance. Moreover, subscription or retainer models are gaining traction among biopharma firms with ongoing testing needs, providing bundled services and cost efficiencies through long-term commitments. These pricing approaches collectively offer flexibility, transparency, and scalability, enabling Contract Research Organizations (CROs) to meet increasing demand while facilitating efficient biologics development and quality assurance. Such factors are expected to drive the market over the estimated time period.

Service Insights

The bioburden testing services segment led the market with the largest revenue share of 19.3% in 2025. The segment growth is driven by its important role in ensuring the sterility and safety of biopharmaceutical products. Bioburden testing is essential for detecting microbial contamination in raw materials, intermediates, and finished products and is a regulatory requirement for biologics, vaccines, and cell and gene therapies. Moreover, the increasing production of biologics and sterile pharmaceuticals, coupled with stringent regulatory guidelines from agencies like the FDA and EMA, is driving the demand for bioburden testing.

The cell line authentication and characterization tests segment is expected to grow at the fastest CAGR over the forecast period. The growth is driven by rising adoption of cell-based therapies, regenerative medicine, and biologics production. In addition, the expansion of research in monoclonal antibodies, personalized medicine, and biosimilars has further increased the need for comprehensive cell line characterization. In addition, regulatory agencies are enforcing stricter guidelines for cell line authentication to minimize the risks associated with misidentified or contaminated cell cultures, further driving the demand for advanced characterization techniques such as short tandem repeat (STR) profiling, karyotyping, and next-generation sequencing (NGS).

Application Insights

The vaccine & therapeutics segment led the biological safety testing services market with the largest revenue share of 41.6% in 2025. The segment growth is due to the high demand for rigorous safety assessments in vaccine production and biopharmaceutical therapies. The rapid expansion of vaccine development, particularly in response to emerging infectious diseases and seasonal outbreaks, is driving the need for extensive bioburden and sterility testing, as well as endotoxin assessments. Moreover, the increasing adoption of monoclonal antibodies and recombinant protein therapies is further contributing to the segment growth.

The cell and gene therapy segment is expected to grow at the fastest CAGR over the forecast period, driven by the expanding pipeline of advanced therapies and increasing regulatory scrutiny. These therapies involve genetically modified cells, viral vectors, and complex biologics, necessitating specialized safety testing, including viral clearance studies, mycoplasma detection, and cell line authentication. With approximately 3,700 cell and gene therapy products in development globally and more than 100 already approved, the demand for comprehensive safety testing is projected to increase in the coming years. Such factors are expected to drive the market growth over the estimated time period.

End Use Insights

The biopharmaceutical companies segment led the biological safety testing services industry with the largest revenue share of 55.0% in 2025. This segment is driven byincreasing production of biologics, biosimilars, and advanced therapies that require stringent safety assessments. Biopharmaceutical companies are constantly developing monoclonal antibodies, vaccines, cell and gene therapies, and other complex biologics, which require proper sterility evaluations and viral clearance studies. Therefore, with the growing pipeline of biologics and personalized medicines, the regulatory agencies are enforcing stricter safety guidelines, further increasing the demand for these services.

The academic and research institutions’ segment is expected to grow at the fastest CAGR over the forecast period. The increasing investments in biomedical research, cell and gene therapy studies, and vaccine development. The universities and research centers are increasingly focusing on innovative drug discovery and preclinical studies, which is subsequently increasing the demand for these services to ensure the integrity and safety of experimental biologics. In addition, increasing government funding and collaborations with biopharmaceutical companies are driving the research in regenerative medicine and personalized therapies, necessitating rigorous contamination and sterility testing.

Regional Insights

The North America biological safety testing services market accounted for the largest revenue share of 33.3% in 2025 due to the region’s well-established biopharmaceutical industry, stringent regulatory requirements, and increasing R&D investments in biologics and advanced therapies. The region’s strong presence of key market players, along with the growing focus on cell and gene therapies, is further boosting demand for comprehensive safety testing services.

U.S. Biological Safety Testing Services Market Trends

The U.S. biological safety testing services industry’s growth is driven by the significant presence of the FDA’s stringent regulatory framework, continuous innovation in biologics, and significant government funding for life sciences research. Moreover, the rising adoption of biosimilars and an increasing number of clinical trials for novel therapies are among the factors driving the country’s market growth.

Europe Biological Safety Testing Services Market Trends

The biological safety testing services industry in Europe is experiencing growth due to the region’s expanding pharmaceutical industry and evolving regulatory environment. Moreover, the increasing adoption of biosimilars and personalized medicine, as well as regulatory enforcement by the European Medicines Agency (EMA), is boosting demand for these services. The region’s focus on advanced biopharmaceutical manufacturing and quality control is further fueling the demand for these services. Such factors are expected to drive the market.

The biological safety testing services market in Germany is anticipated to grow significantly over the forecast period, driven by its robust pharmaceutical manufacturing industry. The country’s strong focus on R&D and quality assurance is driving the market growth. Moreover, advanced regulatory standards and increasing adoption of automated testing technologies are also fueling market growth.

The UK biological safety testing services market held a significant revenue share in 2025. The country’s market growth is driven by its expanding biotechnology sector, increasing government support for life sciences research, and growing investment in gene and cell therapy development. Moreover, the growing presence of globally recognized research institutions is further contributing to the market expansion.

Asia Pacific Biological Safety Testing Services Market Trends

The Asia Pacific biological safety testing services industry is projected to grow at the highest CAGR over the forecast period. The growth of the market is mainly due to increased biopharmaceutical production, rising clinical trial activity, and government initiatives to strengthen biotechnology research. The demand for cost-effective testing services is further fueling outsourcing to CROs in the region.

The biological safety testing services market in China is expected to grow over the forecast period. The growth is driven by heavy investments in vaccine production and an improving regulatory landscape. Moreover, the growing government’s focus on self-sufficiency in biologics manufacturing is further boosting the adoption of these services in the country.

The Japan biological safety testing services market is witnessing significant growth over the forecast period. The growth is due to the country’s aging population and increasing focus on regenerative medicine and cell therapies. The country’s robust pharmaceutical industry and regulatory advancements in gene therapy are also contributing to market expansion.

The biological safety testing services market in India is experiencing considerable growth due to the country’s expanding contract research and manufacturing sector and its cost-effective biologic production capabilities. Moreover, growing government initiatives to promote biotech innovation and attract foreign investments are further driving the country’s market growth.

Latin America Biological Safety Testing Services Market Trends

Latin America’s biological safety testing services industry is gaining traction as regional biopharmaceutical manufacturing, vaccine production, biosimilar development, and clinical research activity expand. The demand for sterility, endotoxin, bioburden, viral safety, and residual contamination testing is increasing as local manufacturers align with international quality standards. Brazil, Mexico, and Argentina remain key contributors due to their established pharmaceutical bases and growing biologics capabilities.

The biological safety testing services market in Brazil represents the leading opportunity within Latin America due to its strong pharmaceutical manufacturing base, vaccine production ecosystem, and expanding biosimilar development activity. The country’s demand for biological safety testing is supported by local biologics manufacturing, public-sector vaccine procurement, and a growing regulatory emphasis on product quality and contamination control. The market is also benefiting from investments in biologics capacity and public-private healthcare collaboration.

Middle East & Africa Biological Safety Testing Services Market Trends

The Middle East & Africa biological safety testing services industry is gradually expanding, driven by healthcare infrastructure development, increasing pharmaceutical localization, vaccine security initiatives, and rising interest in biologics and advanced therapies. Countries such as the UAE, Saudi Arabia, and South Africa are strengthening regulatory frameworks and investing in domestic pharmaceutical capabilities, creating demand for GMP-compliant safety testing.

The UAE biological safety testing services market is emerging as a strategic opportunity in the Middle East, driven by a focus on healthcare innovation, pharmaceutical localization, and life sciences infrastructure development. The UAE’s position as a regional healthcare and logistics hub supports outsourcing opportunities for testing laboratories serving nearby Gulf markets. The growth is supported by government-backed healthcare diversification, regulatory modernization, and investment in biotechnology, diagnostics, and vaccine-related capabilities, although advanced biosafety testing capacity remains developing.

Key Biological Safety Testing Services Companies Insights

Market players are undertaking various strategic initiatives, such as the launch of new product innovations, collaborations, partnerships, and mergers & acquisitions, to strengthen their service offering and provide a competitive advantage. For instance, in October 2024, Merck inaugurated a new USD 300.9 million biosafety testing facility in Rockville, U.S. This 23,000-square-meter facility consolidates biosafety testing, analytical development, and cell bank manufacturing services under one roof, enhancing efficiency and collaboration among scientists.

Key Biological Safety Testing Services Companies

The following key companies have been profiled for this study of the biological safety testing services market.

• Charles River Laboratories International, Inc.
• Lonza Group AG
• Merck KGaA
• SGS SA
• Eurofins Scientific
• WuXi AppTec
• Thermo Fisher Scientific Inc.
• Sartorius AG
• Toxikon Corporation
• bioMérieux SA

Recent Developments

• In October 2024, SGS SA announced to expand its biopharmaceutical testing services to address the increasing global demand for large-molecule drug development. This initiative strengthens its support for biologics across various stages, including cell bank safety assessment, product characterization, method development, and final product release.
• In August 2024, SGS SA announced the launch of specialized services in North America, reinforcing its commitment to supporting the growing demand for biologics and advanced therapies. These services focus on large molecule bioanalysis, pharmacokinetics, immunogenicity, and biomarker analysis, catering to the expanding pipeline of monoclonal antibodies, gene therapies, and cell-based therapeutics.
• In May 2023, Charles River Laboratories entered into a partnership agreement with Wheeler Bio to establish and operate a RightSource Laboratory, an embedded quality control (QC) testing facility designed to streamline and accelerate biologics development. This initiative aims to provide in-house, GMP-compliant biological safety testing for early-stage biopharmaceutical companies, reducing time-to-market for innovative therapeutics.

Global Biological Safety Testing Services Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biological safety testing services market report based on service, application, end use, and region:

• Service Outlook (Revenue, USD Million/Billion, 2021 – 2033)
  • Bioburden Testing Services
  • Endotoxin Testing Services
  • Sterility Testing Services
  • Viral Clearance and Validation Services
  • Cell Line Authentication and Characterization Tests
  • Residual Host Contamination Testing Services
  • Adventitious Agent Detection Testing Services
  • Others
• Application Outlook (Revenue, USD Million/Billion, 2021 – 2033)
  • Vaccine & Therapeutics
    • Monoclonal Antibodies
    • Vaccines
    • Recombinant Protein
  • Cell and Gene Therapy
  • Blood & Blood Products
  • Tissue & Tissue-based Products
  • Others
• End Use Outlook (Revenue, USD Million/Billion, 2021 – 2033)
  • Biopharmaceutical Companies
  • Pharmaceutical Companies
  • Academic and Research Institutions
  • Others
• Regional Outlook (Revenue, USD Million/Billion, 2021 – 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Norway
    • Denmark
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Oman
    • Qatar

Research Methodology

The biological safety testing services market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each biological safety testing services segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

Table of Contents

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Service
1.2.2. Application
1.2.3. End Use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Top-Down Analysis
1.7.3. Bottom-Up Approach
1.7.4. Multivariate Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Biological Safety Testing Services Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Tariff Impact Analysis
3.6. Value Chain Analysis
3.6.1. Supply Trends
3.6.2. Demand Trends
3.7. Market Analysis Tools
3.7.1. Porter’s Five Forces Analysis
3.7.2. PESTEL by SWOT Analysis
Chapter 4. Biological Safety Testing Services Market: Service Estimates & Trend Analysis
4.1. Service Market Share, 2025 & 2033
4.2. Service Type Segment Dashboard
4.3. Biological Safety Testing Services Market: Service Movement Analysis
4.4. Global Biological Safety Testing Services Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million/Billion)
4.5. Bioburden Testing Services
4.5.1. Bioburden Testing Services Market Estimates & Forecasts, 2021 to 2033 (USD Million/Billion)
4.6. Endotoxin Testing Services
4.6.1. Endotoxin Testing Services Market Estimates & Forecasts, 2021 to 2033 (USD Million/Billion)
4.7. Sterility Testing Services
4.7.1. Sterility Testing Services Market Estimates & Forecasts, 2021 to 2033 (USD Million/Billion)
4.8. Viral Clearance and Validation Services
4.8.1. Viral Clearance and Validation Services Market Estimates & Forecasts, 2021 to 2033 (USD Million/Billion)
4.9. Cell Line Authentication and Characterization Tests
4.9.1. Cell Line Authentication and Characterization Tests Market Estimates & Forecasts, 2021 to 2033 (USD Million/Billion)
4.10. Residual Host Contamination Testing Services
4.10.1. Residual Host Contamination Testing Services Market Estimates & Forecasts, 2021 to 2033 (USD Million/Billion)
4.11. Adventitious Agent Detection Testing Services
4.11.1. Adventitious Agent Detection Testing Services Market Estimates & Forecasts, 2021 to 2033 (USD Million/Billion)
4.12. Others
4.12.1. Others Market Estimates & Forecasts, 2021 to 2033 (USD Million/Billion)
Chapter 5. Biological Safety Testing Services Market: Application Estimates & Trend Analysis
5.1. Application Market Share, 2025 & 2033
5.2. Application Segment Dashboard
5.3. Global Biological Safety Testing Services Market: Application Movement Analysis
5.4. Global Biological Safety Testing Services Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million/Billion)
5.5. Vaccine & Therapeutics
5.5.1. Vaccine & Therapeutics Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
5.5.2. Monoclonal Antibodies
5.5.2.1. Monoclonal Antibodies Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
5.5.3. Vaccines
5.5.3.1. Vaccines Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
5.5.4. Recombinant Protein
5.5.4.1. Recombinant Protein Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
5.6. Cell and Gene Therapy
5.6.1. Cell and Gene Therapy Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
5.7. Blood & Blood Products
5.7.1. Blood & Blood Products Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
5.8. Tissue & Tissue-based Products
5.8.1. Tissue & Tissue-based Products Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
5.9. Others
5.9.1. Others Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
Chapter 6. Biological Safety Testing Services Market: End Use Estimates & Trend Analysis
6.1. End Use Market Share, 2025 & 2033
6.2. End Use Segment Dashboard
6.3. Biological Safety Testing Services Market: End Use Movement Analysis
6.4. Global Biological Safety Testing Services Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million/Billion)
6.5. Biopharmaceutical Companies
6.5.1. Biopharmaceutical Companies Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
6.6. Pharmaceutical Companies
6.6.1. Pharmaceutical Companies Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
6.7. Academic and Research Institutions
6.7.1. Academic and Research Institutions Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
6.8. Others
6.8.1. Others Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
Chapter 7. Biological Safety Testing Services Market: Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Biological Safety Testing Services Market: Regional Movement Analysis
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
7.4. North America
7.4.1. North America Biological Safety Testing Services Market Estimates & Forecasts, By Country, 2021 – 2033 (USD Million/Billion)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. U.S. Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Canada Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Regulatory Framework
7.4.4.3. Mexico Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.5. Europe
7.5.1. Europe Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. UK Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Germany Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. France Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Italy Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Spain Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Denmark Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Sweden Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Regulatory Framework
7.5.9.3. Norway Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.6. Asia Pacific
7.6.1. Asia Pacific Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Japan Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. China Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. India Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Australia Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. South Korea Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Framework
7.6.7.3. Thailand Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.7. Latin America
7.7.1. Latin America Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Brazil Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Argentina Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. South Africa Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Saudi Arabia Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. UAE Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework
7.8.5.3. Kuwait Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.8.6. Oman
7.8.6.1. Key Country Dynamics
7.8.6.2. Regulatory Framework
7.8.6.3. Oman Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
7.8.7. Qatar
7.8.7.1. Key Country Dynamics
7.8.7.2. Regulatory Framework
7.8.7.3. Qatar Biological Safety Testing Services Market Estimates & Forecasts, 2021 – 2033 (USD Million/Billion)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Charles River Laboratories
8.5.1.1. Company overview
8.5.1.2. Financial performance
8.5.1.3. Service benchmarking
8.5.1.4. Strategic initiatives
8.5.2. Lonza Group AG
8.5.2.1. Company overview
8.5.2.2. Financial performance
8.5.2.3. Service benchmarking
8.5.2.4. Strategic initiatives
8.5.3. Merck KGaA
8.5.3.1. Company overview
8.5.3.2. Financial performance
8.5.3.3. Service benchmarking
8.5.3.4. Strategic initiatives
8.5.4. SGS SA
8.5.4.1. Company overview
8.5.4.2. Financial performance
8.5.4.3. Service benchmarking
8.5.4.4. Strategic initiatives
8.5.5. Eurofins Scientific
8.5.5.1. Company overview
8.5.5.2. Financial performance
8.5.5.3. Service benchmarking
8.5.5.4. Strategic initiatives
8.5.6. WuXi AppTec
8.5.6.1. Company overview
8.5.6.2. Financial performance
8.5.6.3. Service benchmarking
8.5.6.4. Strategic initiatives
8.5.7. Thermo Fisher Scientific Inc.
8.5.7.1. Company overview
8.5.7.2. Financial performance
8.5.7.3. Service benchmarking
8.5.7.4. Strategic initiatives
8.5.8. Sartorius AG
8.5.8.1. Company overview
8.5.8.2. Financial performance
8.5.8.3. Service benchmarking
8.5.8.4. Strategic initiatives
8.5.9. Toxikon Corporation
8.5.9.1. Company overview
8.5.9.2. Financial performance
8.5.9.3. Service benchmarking
8.5.9.4. Strategic initiatives
8.5.10. bioMérieux SA
8.5.10.1. Company overview
8.5.10.2. Financial performance
8.5.10.3. Service benchmarking
8.5.10.4. Strategic initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 4 Global Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 5 Global Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 6 North America Biological Safety Testing Services Market Estimates and Forecasts, by Country, 2021 – 2033 (USD Million/Billion)
Table 7 North America Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 8 North America Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 9 North America Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 10 U.S. Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 11 U.S. Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 12 U.S. Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 13 Canada Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 14 Canada Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 15 Canada Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 16 Mexico Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 17 Mexico Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 18 Mexico Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 19 Europe Biological Safety Testing Services Market Estimates and Forecasts, by Country, 2021 – 2033 (USD Million/Billion)
Table 20 Europe Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 21 Europe Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 22 Europe Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 23 UK Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 24 UK Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 25 UK Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 26 Germany Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 27 Germany Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 28 Germany Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 29 France Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 30 France Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 31 France Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 32 Italy Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 33 Italy Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 34 Italy Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 35 Spain Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 36 Spain Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 37 Spain Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 38 Denmark Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 39 Denmark Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 40 Denmark Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 41 Sweden Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 42 Sweden Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 43 Sweden Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 44 Norway Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 45 Norway Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 46 Norway Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 47 Asia Pacific Biological Safety Testing Services Market Estimates and Forecasts, by Country, 2021 – 2033 (USD Million/Billion)
Table 48 Asia Pacific Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 49 Asia Pacific Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 50 Asia Pacific Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 51 Japan Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 52 Japan Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 53 Japan Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 54 China Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 55 China Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 56 China Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 57 India Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 58 India Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 59 India Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 60 Australia Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 61 Australia Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 62 Australia Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 63 Thailand Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 64 Thailand Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 65 Thailand Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 66 South Korea Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 67 South Korea Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 68 South Korea Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 69 Latin America Biological Safety Testing Services Market Estimates and Forecasts, by Country, 2021 – 2033 (USD Million/Billion)
Table 70 Latin America Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 71 Latin America Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 72 Latin America Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 73 Brazil Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 74 Brazil Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 75 Brazil Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 76 Argentina Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 77 Argentina Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 78 Argentina Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 79 Middle East & Africa Biological Safety Testing Services Market Estimates and Forecasts, by Country, 2021 – 2033 (USD Million/Billion)
Table 80 Middle East & Africa Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 81 Middle East & Africa Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 82 Middle East & Africa Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 83 South Africa Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 84 South Africa Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 85 South Africa Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 86 Saudi Arabia Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 87 Saudi Arabia Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 88 Saudi Arabia Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 89 UAE Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 90 UAE Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 91 UAE Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 92 Kuwait Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 93 Kuwait Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 94 Kuwait Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 95 Oman Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 96 Oman Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 97 Oman Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)
Table 98 Qatar Biological Safety Testing Services Market Estimates and Forecasts, by Service, 2021 – 2033 (USD Million/Billion)
Table 99 Qatar Biological Safety Testing Services Market Estimates and Forecasts, by Application, 2021 – 2033 (USD Million/Billion)
Table 100 Qatar Biological Safety Testing Services Market Estimates and Forecasts, by End Use, 2021 – 2033 (USD Million/Billion)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Value-chain-based sizing & forecasting
Fig. 8 QFD model sizing & forecasting
Fig. 9 Bottom-up approach
Fig. 10 Market snapshot
Fig. 11 Segment snapshot 1
Fig. 12 Segment snapshot 2
Fig. 13 Competitive landscape snapshot
Fig. 14 Parent market outlook, 2025 (USD Billion)
Fig. 15 Ancillary market outlook, 2025 (USD Billion)
Fig. 16 Biological Safety Testing Services Market Dynamics
Fig. 17 Porter’s five forces analysis
Fig. 18 PESTEL analysis
Fig. 19 Biological Safety Testing Services Market: Service outlook and key takeaways
Fig. 20 Biological Safety Testing Services Market: Service movement analysis
Fig. 21 Bioburden Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 22 Endotoxin Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 23 Sterility Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 24 Viral Clearance and Validation Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 25 Cell Line Authentication and Characterization Tests Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 26 Residual Host Contamination Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 27 Adventitious Agent Detection Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 28 Others Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 29 Biological Safety Testing Services Market: Application outlook and key takeaways
Fig. 30 Biological Safety Testing Services Market: Application movement analysis
Fig. 31 Vaccine & Therapeutics Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 32 Monoclonal Antibodies Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 33 Vaccines Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 34 Recombinant Protein Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 35 Cell and Gene Therapy Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 36 Blood & Blood Products Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 37 Tissue & Tissue-based Products Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 38 Others Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 39 Biological Safety Testing Services Market: End Use outlook and key takeaways
Fig. 40 Biological Safety Testing Services Market: End Use movement analysis
Fig. 41 Biopharmaceutical Companies Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 42 Pharmaceutical Companies Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 43 Academic and Research Institutions Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 44 Others Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 45 Regional Marketplace: Key Takeaways
Fig. 46 North America Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 47 Key country dynamics
Fig. 48 U.S. Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 49 Key country dynamics
Fig. 50 Canada Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 51 Key country dynamics
Fig. 52 Mexico Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 53 Europe Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 54 Key country dynamics
Fig. 55 UK Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 56 Key country dynamics
Fig. 57 Germany Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 58 Key country dynamics
Fig. 59 France Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 60 Key country dynamics
Fig. 61 Italy Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 62 Key country dynamics
Fig. 63 Spain Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 64 Key country dynamics
Fig. 65 Denmark Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 66 Key country dynamics
Fig. 67 Sweden Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 68 Key country dynamics
Fig. 69 Norway Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 70 Asia Pacific Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 71 Key country dynamics
Fig. 72 Japan Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 73 Key country dynamics
Fig. 74 China Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 75 Key country dynamics
Fig. 76 India Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 77 Key country dynamics
Fig. 78 Australia Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 79 Key country dynamics
Fig. 80 Thailand Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 81 Key country dynamics
Fig. 82 South Korea Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 83 Latin America Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 84 Key country dynamics
Fig. 85 Brazil Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 86 Key country dynamics
Fig. 87 Argentina Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 88 MEA Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 89 Key country dynamics
Fig. 90 South Africa Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 91 Key country dynamics
Fig. 92 UAE Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 93 Key country dynamics
Fig. 94 Saudi Arabia Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 95 Key country dynamics
Fig. 96 Kuwait Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 97 Key country dynamics
Fig. 98 Qatar Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 99 Key country dynamics
Fig. 100 Oman Biological Safety Testing Services Market Estimates and Forecasts, 2021 – 2033 (USD Million/Billion)
Fig. 101 Key country dynamics
Fig. 102 Participant Categorization
Fig. 103 Company Market Position Analysis
Fig. 104 Strategic Framework

---

---